Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
EX-99.1
This press release announces a registered direct offering of 750,000 Class A Ordinary Shares at $1.00 per share, generating approximately $750,000 in gross proceeds. The offering is structured as a registered direct offering (not a public offering) to institutional investors, which is a classic dilutive equity issuance. The disclosure explicitly references the shelf registration statement (Form F-3, File No. 333-291149) and prospectus supplement, confirming this is a registered securities offering that will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
Goldman Sachs Private Credit Corp. completed an unregistered sale of Class I, S, and D shares totaling approximately $83.9 million to accredited investors and non-U.S. persons, exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-01
Item 3.02
Surf Air Mobility issued unregistered equity securities in connection with the debt refinancing, including shares of common stock issuable upon conversion of the $16.9 million convertible note and warrants issued to lenders, with the company agreeing to file a registration statement covering resale of warrant shares.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
CVC-PE Global Private Equity Fund, LP completed an unregistered private placement of limited partnership units totaling approximately $55.4 million on June 1, 2026, comprising 391,131 Class R-S Units, 120,221 Class R-I Units, and 455 Class C Units. The offering was conducted as part of the Fund's continuous private offering under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 8.01
Curbline Properties entered into an underwriting agreement on June 29, 2026, to offer and sell 10,000,000 shares of common stock on a forward basis, with the offering closing on July 1, 2026. The company also entered into forward sale agreements with forward purchasers. This is a material dilutive equity issuance—a forward offering of common stock that will result in the delivery of 10 million shares within approximately 18 months, with net proceeds intended for general corporate purposes including property acquisitions, debt repayment, and capital expenditures. The magnitude and structure (forward sale with underwriter involvement) are hallmarks of a material capital-raising event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
MSD Investment Corp. issued 9,574,468 shares of common stock for approximately $225.0 million on June 26, 2026, pursuant to subscription agreements with stockholders. The issuance was made under Section 4(a)(2) of the Securities Act and Regulation D, relying on accredited investor representations. This is a classic unregistered equity issuance under Item 3.02, representing a material capital raise that would affect investor assessment of the company's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-01
Item 8.01
The filing discloses a special dividend of Series O Convertible Preferred Stock paid on March 4, 2026, followed by the automatic conversion of all outstanding Series O Preferred Stock into Common Stock on June 25, 2026, at a conversion ratio of 3.209 shares of Common Stock per preferred share. This conversion resulted in 4,857,211 shares of Common Stock outstanding and an additional 839,000 shares issuable upon warrant exercise, representing substantial dilution to existing common shareholders. While the event involves both a dividend distribution and a conversion, the material impact centers on the dilutive issuance of common shares through the preferred stock conversion mechanism.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-01
Item 1.01
INmune Bio entered into a warrant inducement agreement allowing holders to exercise 647,112 warrants at a reduced exercise price of $1.40 (down from $1.95) and receive 647,112 shares of common stock, with the Company expecting to receive $905,957 in aggregate consideration. While this involves warrant exercise rather than a direct unregistered equity issuance, the economic substance is a dilutive capital raise through the inducement of warrant conversion at favorable terms to holders, generating cash proceeds and increasing share count. The extension of remaining warrant maturity to December 31, 2027 further incentivizes future dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-01
Item 3.02
SunPower closed a $10 million share exchange on July 1, 2026, whereby convertible note holders exchanged cash interest payments due on the notes for 19.3 million shares of common stock issued under Section 4(a)(2) exemption. This unregistered equity issuance materially restructures the company's capital obligations by converting future cash interest payments into equity, significantly diluting existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
EX-99.1
CollPlant announced a private placement of 7,647,061 unregistered ordinary shares plus warrants (series A and B) at $0.34 per share, raising approximately $2.6 million. This is a classic dilutive equity issuance under Section 4(a)(2) and Regulation D, with unregistered securities sold to private investors. The company explicitly states the securities are unregistered and will require a registration statement for resale, and the warrants provide additional dilution potential (22.9 million additional shares if both series are exercised). For a small-cap biotech company with a history of significant losses and capital needs, this represents a material dilutive financing event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
The 6-K discloses the closing of a private placement of 15,841,585 Class A ordinary shares at $1.01 per share for approximately $16.0 million in gross proceeds. This is an unregistered equity issuance under Regulation S, which is a dilutive capital raise. The disclosure explicitly references the subscription agreement and closing date (June 29, 2026), making this a completed dilutive issuance material to investors assessing the registrant's capital structure and ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-01
Item 1.01
On July 1, 2026, Actelis Networks entered into an Exchange and Amendment Agreement with White Lion Capital LLC to issue 9,850,000 shares of common stock (comprising direct shares, pre-funded warrants, and common warrants) in exchange for White Lion's rights under the original Common Stock Purchase Agreement. This unregistered private placement, relying on Section 4(a)(2) and Regulation D exemptions, represents substantial dilution to existing shareholders and was triggered by the Company's Nasdaq delisting in April 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 1.01
Cadrenal Therapeutics completed a private placement of 960,000 shares of common stock (or pre-funded warrants), Series C-1 and C-2 warrants, and placement agent warrants under Section 4(a)(2) and Regulation D exemptions, raising $3.0 million in gross proceeds at $3.1249 per unit, with up to $5.8 million in additional potential proceeds from warrant exercises. The unregistered securities extend the company's cash runway into Q1 2027 (or H2 2027 if warrants are exercised) and are subject to registration rights obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 1.01
Neurogene entered into an underwriting agreement to issue 3.5 million shares of common stock at $30.00 per share, plus 666,666 pre-funded warrants, with underwriters exercising a full 30-day option for an additional 624,999 shares, expected to raise approximately $134.8 million in net proceeds.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-01
Item 3.02
Radnostix issued unregistered equity securities to the sellers, including stock closing consideration, regulatory milestone payment shares, and sales milestone payment shares, in a transaction exempt under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
The Company exchanged 1,830 shares of Series B Preferred Stock (aggregate stated value $1,830,000) for 11,000,786 shares of common stock in unregistered transactions under Section 3(a)(9) of the Securities Act, representing a significant equity dilution event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
The filing discloses entry into an ATM (At-The-Market) Sales Agreement on June 30, 2026, under Item 1.01, authorizing the sale and issuance of $18.5 million in common stock shares through Bancroft Capital, LLC. This is a classic dilutive equity issuance that would materially affect existing shareholders through dilution and is a significant capital-raising event for the company.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-01
EX-99.1
PowerBank closed a registered direct offering of 7,000,000 common shares to institutional investors, raising U.S.$4.2 million. This is a dilutive equity issuance under an effective shelf registration statement (Form F-10), representing a material capital raise that increases share count and dilutes existing shareholders. The offering was made pursuant to a registered prospectus supplement, consistent with a registered direct offering structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
The filing discloses entry into a Placement Agent Agreement on June 30, 2026, for the sale of 35,555 units consisting of 71,110 shares of common stock and 35,555 warrants at $18.00 per unit, generating gross proceeds of $639,990. This is a registered direct offering of equity securities (shares and warrants) that dilutes existing shareholders. The transaction closed on June 30, 2026, and the securities were issued pursuant to an effective Form S-3 shelf registration statement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-01
Item 1.01
Mama's Creations entered into an underwriting agreement for a registered public offering of 5,555,556 shares of common stock at $18.00 per share, generating approximately $100 million in gross proceeds ($94 million net, potentially $115 million with underwriter option). This material equity issuance will dilute existing shareholders and materially affect the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-01
OneMedNet entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville on July 1, 2026, granting the option to sell up to $25 million of Common Stock at 97% of market price. The agreement includes an Exchange Cap of 11,386,834 shares (19.99% of outstanding shares), representing a significant dilutive issuance arrangement. This is a classic PIPE-like structure requiring a resale registration statement, disclosed under Item 1.01 as a material definitive agreement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-01
Item 8.01
Idaho Copper Corporation announced the pricing and completion of an underwritten public offering of common stock and warrants for approximately $18 million gross proceeds at $4.85 per share, with an underwriter option to purchase additional shares to cover over-allotments. This is a material equity issuance that raises capital and creates dilution to existing shareholders. While the filing also mentions NYSE American listing approval, the core material event disclosed in Item 8.01 is the public offering of equity securities.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-07-01
Lloyds Banking Group announces the issuance and admission to trading of 215,648,529 ordinary shares during the period 7 May to 30 June 2026 to satisfy awards under the Company's share plans. This represents a dilutive equity issuance that increases the outstanding share count from approximately 58.1 billion to 58.3 billion shares. While the shares are issued under pre-authorized block admissions (routine for employee equity plans), the magnitude of the issuance and its dilutive effect on existing shareholders constitute a material capital event requiring disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-01
Item 3.02
Inuvo completed a registered direct offering of approximately 2.97 million shares of common stock at $1.00 per share and a concurrent private placement of Class A and Class B warrants to purchase up to 2.97 million shares each, raising approximately $12.97 million in gross proceeds and materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-01
Item 3.02
Energy Vault disclosed an unregistered issuance of an Amended and Restated AR Convertible Debenture under Section 4(a)(2) exemption, representing a dilutive equity instrument with conversion rights that creates potential shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
Stonepeak-Plus Infrastructure Fund LP completed an unregistered private offering of limited partnership units totaling approximately $28.996 million to third-party investors on June 1, 2026, structured as a Section 4(a)(2) and Regulation D exempt offering. This represents a material capital raise with potential dilution to existing unit holders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Item 1.01
Nuvectis entered into an underwriting agreement on June 29, 2026 to conduct a registered public offering of 5,000,000 shares of common stock at $20.00 per share, generating $100 million in gross proceeds (or $115 million if underwriters exercise their 30-day option for 750,000 additional shares), resulting in net proceeds of approximately $93–107 million after underwriting fees.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Item 3.02
Tilray issued 2,638,341 shares of common stock in unregistered private debt-for-equity exchange transactions between June 15-24, 2026, exchanging $12 million principal of convertible notes for equity. This is a dilutive issuance of unregistered equity securities under Section 3(a)(9) of the Securities Act, disclosed under Item 3.02, representing material shareholder dilution and a significant capital restructuring event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-30
EX-99.2
Elevra Lithium issued 5,276,387 unquoted options expiring 31 December 2028 with an exercise price of A$4.80 on 30 June 2026 as the second tranche of a placement previously announced in August 2025. The issuance of unquoted equity securities represents a material dilutive capital event affecting shareholder ownership and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Item 3.02
The Company issued 2.5 million warrants (937,500 to Sponsor and 1,562,500 to Cantor) at $2.00 per warrant for $5 million in gross proceeds in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-30
Item 8.01
The Company disclosed a continuous private placement of Common Shares under Section 4(a)(2) and Regulation D, with approximately $4.8 million in subscriptions received on June 1, 2026, and an intention to continue monthly sales at NAV, representing an ongoing unregistered equity issuance that dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-30
Item 8.01
The Company is conducting a continuous private placement of Common Shares under Section 4(a)(2) and Regulation D, with approximately $2.5 million in subscriptions received on June 1, 2026, and an intention to continue monthly sales at NAV.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Item 3.02
Virginia Electric & Power Company issued 6,046 shares of common stock to its parent Dominion Energy for approximately $450 million in a transaction exempt from registration under Section 4(a)(2) of the Securities Act. This is a classic unregistered equity issuance disclosed under Item 3.02, and the $450 million proceeds used to reduce intercompany debt represent a material capital transaction that would affect a reasonable investor's assessment of the company's capital structure and leverage.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-30
Item 8.01
BlackRock registered up to 12,035,866 shares of common stock for issuance upon redemption of SubCo Units held by sellers of the HPS Investment Partners acquisition. The registration covers both closing-date consideration shares (7,606,927) and deferred consideration units (4,428,939) contingent on post-closing milestones. This is a dilutive equity issuance tied to an M&A transaction, with the prospectus supplement filed to register the shares for future redemption/exchange. While the HPS Transaction itself closed on July 1, 2025, this Item 8.01 disclosure addresses the registration mechanics for the equity consideration component, which is material to shareholders as it represents significant potential dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-30
Item 1.01
Virtuix amended three warrants to reduce the exercise price from $4.00 to $3.00 per share, making the warrants more likely to be exercised and diluting existing shareholders. While technically an amendment rather than a new issuance, the material reduction in exercise price substantially increases the probability of warrant exercise and dilution, which is the core concern underlying the dilutive_issuance category. The amendment to existing financing warrants with a major investor (Streeterville Capital) represents a material capital structure change.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-30
The Company entered into a Securities Purchase Agreement on June 29, 2026, to issue a $2.17 million convertible promissory note (with $160,000 original issue discount) and 325,000 ADSs as pre-delivery shares to an institutional investor. This is a private placement of convertible debt with equity components, which dilutes existing shareholders and raises capital through an unregistered issuance—a classic dilutive_issuance event. The materiality is clear given the size ($2M+ principal) and the explicit equity component (325,000 ADSs).
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-30
EX-99.4
Trident Digital Tech Holdings Ltd has entered into a share subscription agreement to issue 901,408,450 Class B ordinary shares to founder and CEO Soon Huat Lim by conversion of an outstanding US$8,000,000 debt at a conversion price of US$0.008875 per share, with the shares issued under Regulation D and Regulation S private placement exemptions as unregistered securities.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-06-30
The 6-K discloses a Securities Purchase Agreement dated April 13, 2026, under which the Company sold Class A ordinary shares to purchasers, closing April 17, 2026. The filing announces a waiver of the 180-day lock-up restriction and grants registration rights for resale of those securities. This is a private placement of equity securities with registration rights, a hallmark of dilutive issuance activity. While the SPA itself closed in April, the June 29 waiver and registration-rights grant materially accelerate the liquidity and resale potential of those shares, making this a material capital event affecting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-30
Item 1.01
Rain Enhancement Technologies entered into an at-the-market (ATM) sales agreement with Needham & Company to offer and sell up to $3.5 million of Class A common stock. This is a dilutive equity issuance mechanism that allows the company to raise capital by selling shares at market prices, which is material to investors as it signals potential dilution and the company's capital needs. The filing explicitly describes this as an "at the market offering" under Rule 415(a)(4), a classic ATM arrangement typical of dilutive issuances.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-30
EX-99.1
This press release announces a $3.5 million registered direct offering and concurrent private placement of pre-funded warrants and warrants by Biodexa Pharmaceuticals. The offering includes 282,952 ADSs at $2.85 per ADS in the registered portion, plus pre-funded warrants and multiple series of unregistered warrants (Series M, N, and O) to purchase over 2.2 million ADSs in aggregate. The private placement components and unregistered warrant issuances are classic dilutive equity financing mechanisms, particularly material for a clinical-stage biopharmaceutical company raising capital for development programs.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-30
EX-99.1
Azul announced the issuance of 6,904,589 Subscription Warrants – Series 4, which grant holders the right to subscribe for common shares of the Company. This is a dilutive equity issuance that expands the potential share base and represents a capital-raising mechanism. The warrants are exercisable until June 30, 2027, and will trade on B3 beginning July 2, 2026, making this a material capital event affecting existing shareholders' ownership percentages.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-30
Item 1.01
Creative Realities entered into an underwriting agreement on June 29, 2026, to issue 2,528,571 shares of common stock at $3.50 per share and 900,000 pre-funded warrants at $3.49 per warrant, with expected gross proceeds of approximately $12 million. The registered public offering was announced and priced on June 30, 2026, with proceeds intended for working capital, debt paydown, and potential acquisitions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-30
Item 8.01
The Company reports exercise of warrants to purchase 1,361,500 shares for approximately $2.7 million in gross proceeds, resulting in approximately 19% dilution to existing shareholders and a material increase in share count.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-30
EX-99.1
PowerBank announced a registered direct offering of 7,000,000 common shares to institutional investors for approximately $4.2 million gross proceeds. This is a direct equity issuance under an effective Form F-10 shelf registration, representing dilution to existing shareholders. The transaction is material as it affects capitalization and is explicitly disclosed as a securities purchase agreement with institutional investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Dreamland Limited entered into a securities purchase agreement on June 25, 2026, to issue 380,000 Class A ordinary shares at US$3.75 per share for aggregate gross proceeds of US$1,425,000. The shares were issued in an unregistered offshore transaction to a non-U.S. person under Regulation S, with transfer restrictions and restrictive legends. This is a classic private placement of unregistered equity securities, which is material to investors as it represents dilution and a capital raise.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
The filing discloses a private placement (PIPE) of approximately $2,000,000 in unregistered securities, including pre-funded warrants and common stock warrants, closed on June 29, 2026. Item 1.01 describes the Securities Purchase Agreement and Item 3.02 explicitly confirms the unregistered sale under Section 4(a)(2) and Regulation D Rule 506(b). This is a classic dilutive equity issuance raising capital through warrant and equity instruments, material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-06-30
Item 3.02
Nu-Med Plus issued unregistered Series A Preferred Stock to multiple parties (Hayde, Merrell, and Hock) in consideration for services and as part of the Avid Gold Ltd exchange transaction, with maximum conversion potential of 110 million common shares, representing substantial dilution to existing shareholders under Section 4(a)(2), Rule 506 (Regulation D), and Regulation S exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Item 1.01
AquaBounty entered into securities purchase agreements on June 25, 2026, issuing 109,223 shares of Series B Convertible Preferred Stock convertible into 2,184,460 shares of common stock for $2.25 million in a private placement pursuant to Section 4(a)(2) and Regulation D. The unregistered sale to accredited investors represents a significant capital-raising event that will materially dilute existing shareholders upon conversion.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Item 3.02
The Company sold approximately 2.0 million shares of common stock for $29.4 million pursuant to subscription agreements with investors, relying on Section 4(a)(2) and Regulation D exemptions from Securities Act registration. This is a classic unregistered equity issuance to accredited investors under Item 3.02, representing a material capital raise that would dilute existing shareholders and affect the registrant's capitalization.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-30
Item 1.01
GAMCO Natural Resources, Gold & Income Trust entered into an amendment to a sales agreement authorizing the offer and sale of up to 2,000,000 common shares through an at-the-market offering, representing a material dilutive equity issuance.
View raw filing on EDGAR →